Canadian application, no grantCanada
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
CA 2442849 A1 · Owner: Dukart, Gary · Inventors: Dukart, Gary; Gibbons, James Joseph Jr.; Frisch, Jurgen Hermann Ernst
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides the use of a combination of an mTOR inhibitor such as a rapamycin and an antimetabolite antineoplastic agent such as gemsitabine or fluorouracil in the treatment of neoplasms.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 5, 2002
GrantedNo grant recorded
Term endedApril 5, 2022
Patent numberCA 2442849 A1
Classification (IPC)A61K45/06 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.